Zhang Ya-chen, Chen Rui-ming, Lu Bao-jing, Rong Ye-zhi
Department of Internal Cardiology, Xinhua Hospital affiliated to Shanghai Jiaotong Medical University School of Medicine, Shanghai, China.
Chin J Integr Med. 2008 Jun;14(2):107-10. doi: 10.1007/s11655-008-0107-3. Epub 2008 Aug 6.
To confirm the effect of Shengmai Injection (, SMI) in improving cardiac function in patients with acute coronary syndrome (ACS) and to explore its influence on inflammatory reaction in patients.
Ninety ACS patients were randomized into two groups, the control group treated with conventional therapy and the SMI group treated with SMI. The patients' cardiac function was noted and the content of high sensitive C-reactive protein (hs-CRP) in venous blood was measured before treatment and 1 week and 3 weeks after treatment, so as to observe and compare their changes between the two groups.
The cardiac output, stroke volume and ejection fraction in the SMI group after 3 weeks of treatment were all higher than those in the control group (P<0.05). The serum content of hs-CRP was reduced in both groups (P<0.05), but the reduction in the SMI group was more significant than that in the control group (P<0.05).
SMI could improve the cardiac function and further inhibit the inflammatory reaction in patients with ACS.
证实生脉注射液（SMI）对改善急性冠状动脉综合征（ACS）患者心功能的作用，并探讨其对患者炎症反应的影响。
将90例ACS患者随机分为两组，对照组采用常规治疗，生脉注射液组采用生脉注射液治疗。记录患者的心功能，并在治疗前、治疗后1周和3周测量静脉血中高敏C反应蛋白（hs-CRP）的含量，以观察和比较两组之间的变化。
治疗3周后，生脉注射液组的心输出量、每搏输出量和射血分数均高于对照组（P<0.05）。两组血清hs-CRP含量均降低（P<0.05），但生脉注射液组降低更显著（P<0.05）。
生脉注射液可改善ACS患者的心功能，并进一步抑制其炎症反应。
